Extracellular vesicle cross-talk between pulmonary artery smooth muscle cells and endothelium during excessive TGF-β signalling: implications for PAH vascular remodelling.


Journal

Cell communication and signaling : CCS
ISSN: 1478-811X
Titre abrégé: Cell Commun Signal
Pays: England
ID NLM: 101170464

Informations de publication

Date de publication:
08 11 2019
Historique:
received: 30 05 2019
accepted: 04 10 2019
entrez: 10 11 2019
pubmed: 11 11 2019
medline: 14 7 2020
Statut: epublish

Résumé

Excessive TGF-β signalling has been shown to underlie pulmonary hypertension (PAH). Human pulmonary artery smooth muscle cells (HPASMCs) can release extracellular vesicles (EVs) but their contents and significance have not yet been studied. Here, we aimed to analyse the contents and biological relevance of HPASMC-EVs and their transport to human pulmonary arterial endothelial cells (HPAECs), as well as the potential alteration of these under pathological conditions. We used low-input RNA-Seq to analyse the RNA cargoes sorted into released HPASMC-EVs under basal conditions. We additionally analysed the effects of excessive TGF-β signalling, using TGF-β1 and BMP4, in the transcriptome of HPASMCs and their EVs. We then, for the first time, optimised Cre-loxP technology for its use with primary cells in vitro, directly visualising HPASMC-to-HPAEC communication and protein markers on cells taking up EVs. Furthermore we could analyse alteration of this transport with excessive TGF-β signalling, as well as by other cytokines involved in PAH: IL-1β, TNF-α and VEGFA. We were able to detect transcripts from 2417 genes in HPASMC-EVs. Surprisingly, among the 759 enriched in HPASMC-EVs compared to their donor cells, we found Zeb1 and 2 TGF-β superfamily ligands, GDF11 and TGF-β3. Moreover, we identified 90 genes differentially expressed in EVs from cells treated with TGF-β1 compared to EVs in basal conditions, including a subset involved in actin and ECM remodelling, among which were bHLHE40 and palladin. Finally, using Cre-loxP technology we showed cell-to-cell transfer and translation of HPASMC-EV Cre mRNA from HPASMC to HPAECs, effectively evidencing communication via EVs. Furthermore, we found increased number of smooth-muscle actin positive cells on HPAECs that took up HPASMC-EVs. The uptake and translation of mRNA was also higher in activated HPAECs, when stimulated with TGF-β1 or IL-1β. HPASMC-EVs are enriched in RNA transcripts that encode genes that could contribute to vascular remodelling and EndoMT during development and PAH, and TGF-β1 up-regulates some that could enhance this effects. These EVs are functionally transported, increasingly taken up by activated HPAECs and contribute to EndoMT, suggesting a potential effect of HPASMC-EVs in TGF-β signalling and other related processes during PAH development.

Sections du résumé

BACKGROUND
Excessive TGF-β signalling has been shown to underlie pulmonary hypertension (PAH). Human pulmonary artery smooth muscle cells (HPASMCs) can release extracellular vesicles (EVs) but their contents and significance have not yet been studied. Here, we aimed to analyse the contents and biological relevance of HPASMC-EVs and their transport to human pulmonary arterial endothelial cells (HPAECs), as well as the potential alteration of these under pathological conditions.
METHODS
We used low-input RNA-Seq to analyse the RNA cargoes sorted into released HPASMC-EVs under basal conditions. We additionally analysed the effects of excessive TGF-β signalling, using TGF-β1 and BMP4, in the transcriptome of HPASMCs and their EVs. We then, for the first time, optimised Cre-loxP technology for its use with primary cells in vitro, directly visualising HPASMC-to-HPAEC communication and protein markers on cells taking up EVs. Furthermore we could analyse alteration of this transport with excessive TGF-β signalling, as well as by other cytokines involved in PAH: IL-1β, TNF-α and VEGFA.
RESULTS
We were able to detect transcripts from 2417 genes in HPASMC-EVs. Surprisingly, among the 759 enriched in HPASMC-EVs compared to their donor cells, we found Zeb1 and 2 TGF-β superfamily ligands, GDF11 and TGF-β3. Moreover, we identified 90 genes differentially expressed in EVs from cells treated with TGF-β1 compared to EVs in basal conditions, including a subset involved in actin and ECM remodelling, among which were bHLHE40 and palladin. Finally, using Cre-loxP technology we showed cell-to-cell transfer and translation of HPASMC-EV Cre mRNA from HPASMC to HPAECs, effectively evidencing communication via EVs. Furthermore, we found increased number of smooth-muscle actin positive cells on HPAECs that took up HPASMC-EVs. The uptake and translation of mRNA was also higher in activated HPAECs, when stimulated with TGF-β1 or IL-1β.
CONCLUSIONS
HPASMC-EVs are enriched in RNA transcripts that encode genes that could contribute to vascular remodelling and EndoMT during development and PAH, and TGF-β1 up-regulates some that could enhance this effects. These EVs are functionally transported, increasingly taken up by activated HPAECs and contribute to EndoMT, suggesting a potential effect of HPASMC-EVs in TGF-β signalling and other related processes during PAH development.

Identifiants

pubmed: 31703702
doi: 10.1186/s12964-019-0449-9
pii: 10.1186/s12964-019-0449-9
pmc: PMC6839246
doi:

Substances chimiques

Bone Morphogenetic Proteins 0
GDF11 protein, human 0
Growth Differentiation Factors 0
Interleukin-1beta 0
Transforming Growth Factor beta 0
Transforming Growth Factor beta3 0
ZEB1 protein, human 0
Zinc Finger E-box-Binding Homeobox 1 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

143

Subventions

Organisme : British Heart Foundation
ID : PG/16/88/32493
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RG/14/3/30706
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RM/17/3/33381
Pays : United Kingdom
Organisme : British Heart Foundation
ID : CH/11/2/28733
Pays : United Kingdom

Références

Arterioscler Thromb Vasc Biol. 2015 Feb;35(2):303-8
pubmed: 25425619
J Am Coll Cardiol. 2019 Jan 22;73(2):190-209
pubmed: 30654892
Circulation. 2006 Apr 18;113(15):1857-64
pubmed: 16606791
Cardiology. 2017;137(1):43-53
pubmed: 28068653
Arterioscler Thromb Vasc Biol. 2016 Mar;36(3):525-33
pubmed: 26800565
Bioinformatics. 2015 Jan 15;31(2):166-9
pubmed: 25260700
Am J Respir Cell Mol Biol. 2018 Oct;59(4):467-478
pubmed: 29676587
J Clin Invest. 2016 Apr 1;126(4):1323-36
pubmed: 26950419
Circulation. 2001 Aug 14;104(7):790-5
pubmed: 11502704
J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D4-12
pubmed: 24355640
Am J Respir Cell Mol Biol. 2014 Oct;51(4):474-84
pubmed: 24932885
Int J Oncol. 2016 Jun;48(6):2310-20
pubmed: 27035755
Mol Ther. 2010 Dec;18(12):2139-45
pubmed: 20978477
Bioinformatics. 2006 Jul 1;22(13):1600-7
pubmed: 16606683
JACC Basic Transl Sci. 2017 Dec 25;2(6):790-807
pubmed: 30062186
Hypertension. 2018 Apr;71(4):729-741
pubmed: 29463625
Genome Biol. 2014;15(12):550
pubmed: 25516281
J Biomol Tech. 2015 Apr;26(1):4-18
pubmed: 25649271
Circulation. 2010 Aug 31;122(9):920-7
pubmed: 20713898
Nat Protoc. 2016 Jan;11(1):87-101
pubmed: 26658469
Sci Rep. 2018 Feb 12;8(1):2823
pubmed: 29434302
Circ Res. 2015 Oct 23;117(10):870-883
pubmed: 26311719
Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2848-53
pubmed: 11880636
Am J Respir Crit Care Med. 1998 Mar;157(3 Pt 1):907-11
pubmed: 9517610
J Cell Biol. 2013 Feb 18;200(4):373-83
pubmed: 23420871
Mol Biol Cell. 2014 Sep 1;25(17):2556-70
pubmed: 24989798
Nat Cell Biol. 2012 Feb 12;14(3):249-56
pubmed: 22327366
J Cell Biochem. 2018 Feb;119(2):2144-2155
pubmed: 28862358
Am J Respir Crit Care Med. 2016 Nov 1;194(9):1140-1151
pubmed: 27115515
Int J Cancer. 2017 Aug 1;141(3):614-620
pubmed: 28445609
Circ Res. 2005 Sep 2;97(5):496-504
pubmed: 16100039
Curr Protoc Bioinformatics. 2015 Sep 03;51:11.14.1-11.14.19
pubmed: 26334920
Gene. 2014 Nov 1;551(1):55-64
pubmed: 25158130
Eur Respir Rev. 2014 Dec;23(134):450-7
pubmed: 25445943
Nat Med. 2013 Jan;19(1):74-82
pubmed: 23263626
Int J Oncol. 2012 Oct;41(4):1337-46
pubmed: 22825629
J Clin Invest. 2016 Apr 1;126(4):1152-62
pubmed: 27035807
Dev Biol. 2007 Oct 15;310(2):454-69
pubmed: 17850784
Nat Commun. 2017 Jan 13;8:14079
pubmed: 28084316
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Cell. 2015 May 21;161(5):1046-1057
pubmed: 26000481
Dev Dyn. 2018 Mar;247(3):492-508
pubmed: 28891150
Sci Transl Med. 2018 Jun 13;10(445):
pubmed: 29899023
J Am Coll Cardiol. 2009 Jun 30;54(1 Suppl):S20-S31
pubmed: 19555855
Am J Respir Cell Mol Biol. 1994 Dec;11(6):664-75
pubmed: 7946395
Oncogene. 2016 Oct 6;35(40):5224-5236
pubmed: 26973246
Lancet Respir Med. 2016 Apr;4(4):306-22
pubmed: 26975810
Ann Intern Med. 2008 Feb 19;148(4):278-83
pubmed: 18283205

Auteurs

Fernando de la Cuesta (F)

Centre for Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh, 47 Little France Crescent, EH16 4TJ, Edinburgh, EH16 4TJ, UK.

Ilaria Passalacqua (I)

Centre for Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh, 47 Little France Crescent, EH16 4TJ, Edinburgh, EH16 4TJ, UK.

Julie Rodor (J)

Centre for Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh, 47 Little France Crescent, EH16 4TJ, Edinburgh, EH16 4TJ, UK.

Raghu Bhushan (R)

Centre for Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh, 47 Little France Crescent, EH16 4TJ, Edinburgh, EH16 4TJ, UK.
Present affiliation: Yenepoya Research Centre, Yenepoya University, Deralakatte, Mangalore, India.

Laura Denby (L)

Centre for Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh, 47 Little France Crescent, EH16 4TJ, Edinburgh, EH16 4TJ, UK.

Andrew H Baker (AH)

Centre for Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh, 47 Little France Crescent, EH16 4TJ, Edinburgh, EH16 4TJ, UK. Andy.Baker@ed.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH